DK3573600T3 - Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering - Google Patents

Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering Download PDF

Info

Publication number: DK3573600T3
Authority: DK; Denmark
Prior art keywords: pepti; delivery; preparing; procedure; stable emulsion
Prior art date: 2017-01-25

Application number

DK18710760.2T

Other languages

English (en)

Inventor

Jean-Pascal Conduzorgues

Original Assignee

Ose Immunotherapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-25

Filing date

2018-01-24

Publication date

2022-05-09

2018-01-24 Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics

2022-05-09 Application granted granted Critical

2022-05-09 Publication of DK3573600T3 publication Critical patent/DK3573600T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
- A61K40/4266—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gynecology & Obstetrics (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Colloid Chemistry (AREA)
General Preparation And Processing Of Foods (AREA)

DK18710760.2T 2017-01-25 2018-01-24 Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering DK3573600T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17305079		2017-01-25
PCT/EP2018/051647 WO2018138110A1 (en)	2017-01-25	2018-01-24	Method for manufacturing a stable emulsion for peptide delivery

Publications (1)

Publication Number	Publication Date
DK3573600T3 true DK3573600T3 (da)	2022-05-09

Family

ID=57965869

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18710760.2T DK3573600T3 (da)	2017-01-25	2018-01-24	Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering

Country Status (25)

Country	Link
US (2)	US11325959B2 (da)
EP (3)	EP4029494B1 (da)
JP (1)	JP7140778B2 (da)
KR (1)	KR102577036B1 (da)
CN (2)	CN110191703B (da)
AR (1)	AR113209A1 (da)
AU (1)	AU2018213890B2 (da)
BR (1)	BR112019014917A2 (da)
CA (1)	CA3047492C (da)
CY (1)	CY1125239T1 (da)
DK (1)	DK3573600T3 (da)
ES (1)	ES2913268T3 (da)
HR (1)	HRP20220605T1 (da)
HU (1)	HUE058717T2 (da)
IL (1)	IL267237B2 (da)
LT (1)	LT3573600T (da)
MX (1)	MX2019008878A (da)
PL (1)	PL3573600T3 (da)
PT (1)	PT3573600T (da)
RS (1)	RS63259B1 (da)
SI (1)	SI3573600T1 (da)
SM (1)	SMT202200189T1 (da)
TW (1)	TWI793099B (da)
WO (1)	WO2018138110A1 (da)
ZA (1)	ZA201905487B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2913268T3 (es)	2017-01-25	2022-06-01	Ose Immunotherapeutics	Método para fabricar una emulsión estable para la administración de péptidos
BR112021011982A2 (pt)	2018-12-21	2021-09-14	Ose Immunotherapeutics	Anticorpo anti-humano-pd-1 humanizado

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2456666T3 (es) *	2003-04-18	2014-04-23	Biotech Synergy, Inc.	Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
ES2545457T3 (es)	2006-10-17	2015-09-11	Oncotherapy Science, Inc.	Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
TWI494319B (zh)	2007-02-21	2015-08-01	Oncotherapy Science Inc	表現腫瘤相關抗原之癌症的胜肽疫苗
MX2010002001A (es)	2007-08-20	2010-03-11	Oncotherapy Science Inc	Peptido cdca1 y agente farmaceutico que comprende elmismo.
US20110104101A1 (en)	2008-03-06	2011-05-05	University Of Medicine And Dentistry Of New Jersey	Immunotherapy for Unresectable Pancreatic Cancer
CN104086625B (zh)	2008-10-22	2016-08-31	肿瘤疗法科学股份有限公司	Rab6kifl/kif20a表位肽及包含它的疫苗
TWI507204B (zh)	2009-05-26	2015-11-11	Oncotherapy Science Inc	Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
EP2292258A1 (en)	2009-08-18	2011-03-09	Pevion Biotech Ltd.	Multiepitope vaccine for Her2/neu-associated cancers
TW201124530A (en)	2009-12-01	2011-07-16	Oncotherapy Science Inc	IMP-3 oligopeptides and vaccines including the same
AU2011225577B2 (en)	2010-03-11	2017-01-19	Oncotherapy Science, Inc.	HJURP peptides and vaccines including the same
TW201216982A (en)	2010-10-21	2012-05-01	Oncotherapy Science Inc	WDHD1 peptides and vaccines including the same
JP2014500001A (ja)	2010-10-21	2014-01-09	オンコセラピー・サイエンス株式会社	Ｃ１８ｏｒｆ５４ペプチドおよびそれを含むワクチン
MY166516A (en)	2010-12-02	2018-07-05	Oncotherapy Science Inc	Tomm34 peptides and vaccines including the same
TW201302800A (zh)	2011-06-10	2013-01-16	Oncotherapy Science Inc	Ｓｅｍａ５ｂ胜肽及含其之疫苗
CA2842887C (en)	2011-08-12	2021-01-19	Oncotherapy Science, Inc.	Mphosph1 peptides and vaccines including the same
RU2633503C2 (ru)	2011-10-28	2017-10-12	Онкотерапи Сайенс, Инк.	Пептиды торк и содержащие их вакцины
EP2785375B1 (en)	2011-11-28	2020-07-22	Merck Patent GmbH	Anti-pd-l1 antibodies and uses thereof
RU2663350C2 (ru)	2012-09-11	2018-08-03	Онкотерапи Сайенс, Инк.	Пептиды ube2t и содержащие их вакцины
CN105163754B (zh)	2012-09-20	2018-01-05	王荣福	前列腺特异性肿瘤抗原及其用途
CA2898457A1 (en)	2013-02-14	2014-08-21	Immunocellular Therapeutics, Ltd.	Ovarian cancer vaccines and vaccination methods
WO2014136453A1 (en)	2013-03-08	2014-09-12	Oncotherapy Science, Inc.	C12orf48 PEPTIDES AND VACCINES CONTAINING THE SAME
WO2014141652A1 (en)	2013-03-11	2014-09-18	Oncotherapy Science, Inc.	Smyd3 peptides and vaccines containing the same
TWI658049B (zh)	2013-03-12	2019-05-01	腫瘤療法科學股份有限公司	Ｋｎｔｃ２胜肽及含此胜肽之疫苗
JP6419693B2 (ja)	2013-04-01	2018-11-07	学校法人久留米大学	腫瘍抗原ペプチド
GB2530236A (en)	2014-04-11	2016-03-23	Univ Nottingham Trent	PAP Peptide analogues
EP3137100B1 (en)	2014-04-15	2023-12-20	University Of Virginia Patent Foundation	Isolated t cell receptors and methods of use therefor
EP2944652A1 (en)	2014-05-13	2015-11-18	Technische Universität München	Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
EP3215184B1 (en) *	2014-11-06	2021-03-03	OSE Immunotherapeutics	Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
EP3313431B1 (en)	2015-06-29	2023-11-15	OSE Immunotherapeutics	Method for inducing early t memory response with short peptides anti-tumor vaccine
ES2913268T3 (es)	2017-01-25	2022-06-01	Ose Immunotherapeutics	Método para fabricar una emulsión estable para la administración de péptidos
CA3081774A1 (en)	2017-11-27	2019-05-31	Ose Immunotherapeutics	Improved treatment of cancer
BR112021011982A2 (pt)	2018-12-21	2021-09-14	Ose Immunotherapeutics	Anticorpo anti-humano-pd-1 humanizado
KR20210107062A (ko)	2018-12-21	2021-08-31	오제 이뮈노테라프틱스	이작용성 항-PD-1/SIRPα 분자
CA3123338A1 (en)	2018-12-21	2020-06-25	Ose Immunotherapeutics	Bifunctional anti-pd-1/il-7 molecule
CA3122899A1 (en)	2018-12-21	2020-06-25	Ose Immunotherapeutics	Bifunctional molecule directed against human pd-1

2018
- 2018-01-24 ES ES18710760T patent/ES2913268T3/es active Active
- 2018-01-24 KR KR1020197024340A patent/KR102577036B1/ko active Active
- 2018-01-24 MX MX2019008878A patent/MX2019008878A/es unknown
- 2018-01-24 LT LTEPPCT/EP2018/051647T patent/LT3573600T/lt unknown
- 2018-01-24 WO PCT/EP2018/051647 patent/WO2018138110A1/en not_active Ceased
- 2018-01-24 CN CN201880007527.3A patent/CN110191703B/zh active Active
- 2018-01-24 HU HUE18710760A patent/HUE058717T2/hu unknown
- 2018-01-24 SI SI201830646T patent/SI3573600T1/sl unknown
- 2018-01-24 CN CN202210293478.2A patent/CN114917189B/zh active Active
- 2018-01-24 PL PL18710760T patent/PL3573600T3/pl unknown
- 2018-01-24 HR HRP20220605TT patent/HRP20220605T1/hr unknown
- 2018-01-24 SM SM20220189T patent/SMT202200189T1/it unknown
- 2018-01-24 RS RS20220413A patent/RS63259B1/sr unknown
- 2018-01-24 BR BR112019014917-1A patent/BR112019014917A2/pt active Search and Examination
- 2018-01-24 US US16/477,534 patent/US11325959B2/en active Active
- 2018-01-24 JP JP2019560481A patent/JP7140778B2/ja active Active
- 2018-01-24 CA CA3047492A patent/CA3047492C/en active Active
- 2018-01-24 DK DK18710760.2T patent/DK3573600T3/da active
- 2018-01-24 EP EP22153774.9A patent/EP4029494B1/en active Active
- 2018-01-24 PT PT187107602T patent/PT3573600T/pt unknown
- 2018-01-24 EP EP25203318.8A patent/EP4649954A3/en active Pending
- 2018-01-24 IL IL267237A patent/IL267237B2/en unknown
- 2018-01-24 EP EP18710760.2A patent/EP3573600B1/en active Active
- 2018-01-24 AU AU2018213890A patent/AU2018213890B2/en active Active
- 2018-01-25 TW TW107102651A patent/TWI793099B/zh active
- 2018-01-25 AR ARP180100167A patent/AR113209A1/es unknown
2019
- 2019-08-20 ZA ZA2019/05487A patent/ZA201905487B/en unknown
2022
- 2022-05-04 US US17/736,113 patent/US11981713B2/en active Active
- 2022-05-18 CY CY20221100337T patent/CY1125239T1/el unknown

Also Published As

Publication number	Publication date
AU2018213890A1 (en)	2019-07-04
AU2018213890B2 (en)	2023-07-20
KR20190107113A (ko)	2019-09-18
US11325959B2 (en)	2022-05-10
HUE058717T2 (hu)	2022-09-28
EP3573600A1 (en)	2019-12-04
EP3573600B1 (en)	2022-03-02
TW201840331A (zh)	2018-11-16
US20220259277A1 (en)	2022-08-18
CN110191703B (zh)	2022-04-08
US11981713B2 (en)	2024-05-14
AR113209A1 (es)	2020-02-19
LT3573600T (lt)	2022-06-27
CN114917189B (zh)	2024-05-14
PT3573600T (pt)	2022-05-11
MX2019008878A (es)	2020-02-13
JP7140778B2 (ja)	2022-09-21
IL267237B1 (en)	2024-06-01
ES2913268T3 (es)	2022-06-01
EP4029494A1 (en)	2022-07-20
KR102577036B1 (ko)	2023-09-08
ZA201905487B (en)	2020-05-27
EP4029494B1 (en)	2025-09-24
US20190345213A1 (en)	2019-11-14
RS63259B1 (sr)	2022-06-30
JP2020505464A (ja)	2020-02-20
IL267237A (en)	2019-08-29
CA3047492A1 (en)	2018-08-02
NZ754471A (en)	2023-12-22
SI3573600T1 (sl)	2022-07-29
IL267237B2 (en)	2024-10-01
PL3573600T3 (pl)	2022-07-11
BR112019014917A2 (pt)	2020-03-31
EP4649954A3 (en)	2025-12-17
WO2018138110A1 (en)	2018-08-02
HRP20220605T1 (hr)	2022-07-08
EP4649954A2 (en)	2025-11-19
TWI793099B (zh)	2023-02-21
SMT202200189T1 (it)	2022-07-21
CN110191703A (zh)	2019-08-30
CA3047492C (en)	2024-01-02
CN114917189A (zh)	2022-08-19
CY1125239T1 (el)	2024-12-13

Publication	Publication Date	Title
DK3398353T3 (da)	2021-11-01	Fremgangsmåde til generering af en tilpasset/personaliseret hovedrelateret overførselsfunktion
DK3396187T3 (da)	2020-06-22	Fremgangsmåde til fremstilling af en glidelejebøsning
HUE051862T2 (hu)	2021-03-29	Stabil, IFNAR1-elleni készítmény
EP3538146A4 (en)	2020-07-15	INFLUENZA VACCINE
DK3361946T3 (da)	2019-10-28	Føringssystem til indføring af en medicinsk nål
PL3419705T3 (pl)	2020-10-05	System dostarczania aerozolu
EP3463228A4 (en)	2020-03-04	INTRAOCULAR ADMINISTRATION OF MEDICINES
DK3294700T3 (da)	2020-04-14	Fremgangsmåde til fremstilling af limonen-4-ol
HUE049338T2 (hu)	2020-09-28	Hüvely implantátum bejuttatására
IL249197A0 (en)	2017-01-31	Stable cannabinoid formulations
DK3609535T3 (da)	2025-08-18	Hbv-vaccine
DK3519094T3 (da)	2020-08-31	System til forberedelse af en prøve
DK3376923T3 (da)	2020-01-20	Fremgangsmåde til tilberedning af en drik
DK3236881T3 (da)	2021-05-03	System til vaccination af fjerkræ
DK3529498T3 (da)	2022-08-15	Diafragma til en centrifugalkompressor
EP3349582A4 (en)	2019-04-24	NOVEL INSECT-INHIBITING PROTEINS
DK3529233T3 (da)	2020-10-12	Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3210276T3 (da)	2025-03-03	Fremgangsmåde til drift af et uafhængigt netværk
DK3749449T3 (da)	2022-04-19	Fremgangsmåde til fremstilling af en sølvimprægnerings-opløsning
EP3704137A4 (en)	2021-08-11	NEW SCAFFOLD-TYPE ANTI-HIV-1 IMMUNOGENS
DK3571394T3 (da)	2021-03-22	Inertireaktion for netstabilitet
DK3727680T3 (da)	2022-07-04	Fremgangsmåde til fremstilling af en separationsmatrix
DK3258901T3 (da)	2020-08-17	Trinforcerende tilbehør til en kørestol
DK3266579T3 (da)	2020-06-15	Fremstillingsform til et rotorblad
DK3408015T3 (da)	2021-11-01	Fremgangsmåde til fremstilling af emulsioner